BACKGROUND AND OBJECTIVES: Evaluation for ischemic heart disease (IHD) is a nonstandardized practice before kidney transplantation. We retrospectively studied pretransplant cardiac evaluation (CE) practices in a national sample of renal allograft recipients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The USRDS data for Medicare beneficiaries transplanted in 1991 to 2004 with Part A&B benefits from dialysis initiation through transplantation were examined. Clinical traits defining "high" expected IHD risk were defined as diabetes, prior IHD, or > or = 2 other coronary risk factors. Pretransplant CE were identified by billing claims for noninvasive stress tests and angiography. Patients were quantified with claims for coronary revascularization procedures between CE and transplant. Post-transplant acute myocardial infarction (AMI) events were abstracted from claims and death records. RESULTS: Among 27,786 eligible patients, 46.3% underwent CE before transplantation. Overall, 9.5% who received CE also received pretransplant revascularization, but only 0.3% of lower-risk patients undergoing CE had revascularization. The adjusted odds of transplant without CE increased sharply with younger age and shorter dialysis duration. Increased likelihood of transplant without CE also correlated with black race, female sex, and certain geographic regions. Among patients transplanted without CE, 3-yr incidence of post-transplant AMI was 3% in lower-risk and 10% in high-risk groups, and varied by individual traits within these groups. Among lower-risk patients transplanted without CE, blacks were higher risk for AMI than whites (adjusted hazards ratio 1.47, 95% CI 1.11-1.93). CONCLUSIONS: Observed practices demonstrate infrequent use of pretransplant revascularization after CE but also raise concern for socio-demographic barriers to evaluation access.
BACKGROUND AND OBJECTIVES: Evaluation for ischemic heart disease (IHD) is a nonstandardized practice before kidney transplantation. We retrospectively studied pretransplant cardiac evaluation (CE) practices in a national sample of renal allograft recipients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The USRDS data for Medicare beneficiaries transplanted in 1991 to 2004 with Part A&B benefits from dialysis initiation through transplantation were examined. Clinical traits defining "high" expected IHD risk were defined as diabetes, prior IHD, or > or = 2 other coronary risk factors. Pretransplant CE were identified by billing claims for noninvasive stress tests and angiography. Patients were quantified with claims for coronary revascularization procedures between CE and transplant. Post-transplant acute myocardial infarction (AMI) events were abstracted from claims and death records. RESULTS: Among 27,786 eligible patients, 46.3% underwent CE before transplantation. Overall, 9.5% who received CE also received pretransplant revascularization, but only 0.3% of lower-risk patients undergoing CE had revascularization. The adjusted odds of transplant without CE increased sharply with younger age and shorter dialysis duration. Increased likelihood of transplant without CE also correlated with black race, female sex, and certain geographic regions. Among patients transplanted without CE, 3-yr incidence of post-transplant AMI was 3% in lower-risk and 10% in high-risk groups, and varied by individual traits within these groups. Among lower-risk patients transplanted without CE, blacks were higher risk for AMI than whites (adjusted hazards ratio 1.47, 95% CI 1.11-1.93). CONCLUSIONS: Observed practices demonstrate infrequent use of pretransplant revascularization after CE but also raise concern for socio-demographic barriers to evaluation access.
Authors: William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: E L Ramos; B L Kasiske; S R Alexander; G M Danovitch; W E Harmon; L Kahana; T J Kiresuk; J F Neylan Journal: Transplantation Date: 1994-02-27 Impact factor: 4.939
Authors: Scott E Friedman; Robert T Palac; David M Zlotnick; Michael C Chobanian; Salvatore P Costa Journal: Clin J Am Soc Nephrol Date: 2011-04-21 Impact factor: 8.237
Authors: Nicola Kumar; Christopher S R Baker; Kakit Chan; Neill Duncan; Iqbal Malik; Andrew Frankel; Damien R Ashby; Adam McLean; Andrew Palmer; Tom D Cairns; David Taube Journal: Clin J Am Soc Nephrol Date: 2011-07-07 Impact factor: 8.237
Authors: Krista L Lentine; Frank P Hurst; Rahul M Jindal; Todd C Villines; Jeffrey S Kunz; Christina M Yuan; Paul J Hauptman; Kevin C Abbott Journal: Am J Kidney Dis Date: 2009-09-23 Impact factor: 8.860
Authors: Xingxing S Cheng; Daniel J Watford; Hiroyuki Arashi; Margaret R Stedman; Glenn M Chertow; Jane C Tan; William F Fearon Journal: Cardiorenal Med Date: 2021-05-25 Impact factor: 4.360
Authors: Charles A Herzog; Mengistu A Simegn; Yifan Xu; Salvatore P Costa; Roy O Mathew; Mohammad C El-Hajjar; Sanjeev Gulati; Rafael A Maldonado; Eric Daugas; Magdelena Madero; Jerome L Fleg; Rebecca Anthopolos; Gregg W Stone; Mandeep S Sidhu; David J Maron; Judith S Hochman; Sripal Bangalore Journal: J Am Coll Cardiol Date: 2021-05-11 Impact factor: 27.203
Authors: Amit K Mathur; Yu-Hui Chang; D Eric Steidley; Raymond L Heilman; Nabil Wasif; David Etzioni; Kunam S Reddy; Adyr A Moss Journal: BMC Nephrol Date: 2019-05-28 Impact factor: 2.388
Authors: Durga Anil K Kanigicherla; Talvinder Bhogal; Katie Stocking; Rajkumar Chinnadurai; Simon Gray; Saad Javed; Christien Fortune; Titus Augustine; Philip A Kalra Journal: PLoS One Date: 2020-10-28 Impact factor: 3.240